Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture.
نویسندگان
چکیده
BACKGROUND Current methods of hormonal emergency contraception (EC) are ineffective in preventing follicular rupture when administered in the advanced pre-ovulatory phase. This study was designed to determine the capacity of ulipristal acetate (UPA), a selective progesterone receptor modulator developed for EC, to block follicular rupture when administered with a follicle of >or=18 mm. METHODS This was a double-blind, crossover, randomized, placebo-controlled study. Thirty-five women contributed with UPA (30 mg. oral) and a placebo cycle. Serial blood sampling for luteinizing hormone (LH), estradiol and progesterone measurements and follicular monitoring by ultrasound were performed before and for 5 days following treatment. Follicular rupture inhibition was assessed in the overall study population and in subgroups of women stratified by when treatment was administered in relation to LH levels (before the onset of the LH surge, after the onset of the surge but before the LH peak or after the LH peak). RESULTS Follicular rupture failed to occur for at least 5 days following UPA administration in 20/34 cycles [59%; 95% confidence interval (CI) (40.7-75.4%)], whereas rupture took place in all cycles within 5 days of placebo intake. When UPA was administered before the onset of the LH surge, or after the onset but before the LH peak, follicle rupture had not occurred within 5 days in 8/8 (100%) and 11/14 [78.6%; 95% CI (49.2-95.3)] cycles, respectively. In contrast, when UPA was given after the LH peak, follicle rupture inhibition was only observed in 1/12 [8.3%; 95% CI (0.2-38.5)] cycles. CONCLUSIONS This study demonstrates that UPA can significantly delay follicular rupture when given immediately before ovulation. This new generation EC compound could possibly prevent pregnancy when administered in the advanced follicular phase, even if LH levels have already begun to rise, a time when levonorgestrel EC is no longer effective in inhibiting ovulation.
منابع مشابه
Ulipristal acetate in emergency contraception: mechanism of action.
These conclusions are shared by most authoritative international drug administrations. The USA FDA just adds that alterations to the endometrium might possibly contribute to UPA efficacy (http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022474s000lbl.pdf), whereas the European Medicines Agency only mentions ovulatory delay (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Prod...
متن کاملCombined pill and GTD.
randomised non-inferiority trial and meta-analysis. Lancet 2010; 375: 555–562. 4 Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006; 108: 1089–1097. 5 von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G, et al; WHO Research Group on Postovulatory Methods of...
متن کاملSelf-triage and clinic waiting times.
randomised non-inferiority trial and meta-analysis. Lancet 2010; 375: 555–562. 4 Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006; 108: 1089–1097. 5 von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G, et al; WHO Research Group on Postovulatory Methods of...
متن کاملUlipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens.
BACKGROUND The days just prior to ovulation are the most crucial for emergency contraception (EC) efficacy. Ulipristal acetate (UPA) and levonorgestrel's (LNG) capacity to inhibit follicular rupture have never been compared directly at this time of the cycle. STUDY DESIGN Raw data from three pharmacodynamics studies with similar methodology were pooled to allow direct comparison of UPA, LNG a...
متن کاملThe need to take a 'new look' at emergency contraception.
©FSRH J Fam Plann Reprod Health Care 2010: 36(1) Background New developments in hormonal emergency contraception (EC) are likely to cause us to rethink both service delivery and the advice that we give to patients about ongoing contraception. ellaOne® [30 mg ulipristal acetate (UPA)] has been marketed since October 2009 and is the subject of a previous commentary in this Journal.1 Biomedical st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Human reproduction
دوره 25 9 شماره
صفحات -
تاریخ انتشار 2010